CLINICAL RESEARCH: CARDIOVASCULAR DISEASE AND RISK
The Deleterious Effects of Hyperglycemia on Platelet Function in Diabetic Patients With Acute Coronary Syndromes
Mediation by Superoxide Production, Resolution With Intensive Insulin Administration
Matthew I. Worthley, MBBS, PhD,
Andrew S. Holmes, PhD,
Scott R. Willoughby, PhD,
Angela M. Kucia, BN, PhD,
Tamila Heresztyn, BSc,
Simon Stewart, PhD, FESC,
Yuliy Y. Chirkov, BSc, PhD,
Christopher J. Zeitz, MBBS, PhD and
John D. Horowitz, MBBS, PhD*
Cardiology Unit, Basil Hetzel Research Institute, The Queen Elizabeth Hospital, University of Adelaide, South Australia, Australia
Manuscript received June 19, 2006;
revised manuscript received August 14, 2006,
accepted August 30, 2006.
* Reprint requests and correspondence: Dr. John D. Horowitz, Cardiology Unit, Department of Medicine, University of Adelaide, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville South, South Australia, Australia 5011. (Email: john.horowitz{at}adelaide.edu.au).
OBJECTIVES: This study sought to assess the determinants of platelet nitric oxide (NO) responsiveness in diabetic patients admitted with acute coronary syndromes (ACS) and the short-term effects of aggressive glycemic control on these factors.
BACKGROUND: Hyperglycemia is an independent risk factor for mortality in both diabetic patients and nondiabetic patients with ACS. The mechanism(s) underlying this observation and potential benefit from its correction remain uncertain. Although a reduction in NO bioavailability has been proposed, this remains untested in the ACS setting.
METHODS: A total of 76 diabetic patients with ACS were studied. Putative correlations between admission blood sugar level (BSL), inhibition of platelet aggregation by the NO donor sodium nitroprusside (SNP), and superoxide (O2
) were assessed. Hyperglycemic patients (n = 60) were randomized to acute glycemic control with intravenous versus subcutaneous insulin, and changes in the aforementioned parameters were compared. Plasma levels of the endogenous inhibitor of NO synthase asymmetric dimethylarginine (ADMA) were also monitored.
RESULTS: There was an inverse correlation between admission BSL and both platelet SNP response (p = 0.007) and ADMA levels (p = 0.045), and a positive correlation with O2
generation (p < 0.001). Intravenous insulin infusion resulted in a greater reduction (p < 0.001) in BSL, differentially improved platelet responsiveness to SNP (p = 0.049), and decreased O2
(p < 0.001) and ADMA levels (p = 0.049).
CONCLUSIONS: A component of platelet dysfunction in diabetic patients with ACS is impaired responsiveness to the anti-aggregatory effects of NO, probably reflecting increased NO clearance by O2
. This phenomenon is reversed by acute aggressive glycemic control. These findings provide a further rationale for use of insulin therapy in acute myocardial infarction and suggest its extension to ACS patients.
|
Abbreviations and Acronyms
| | ACS = acute coronary syndromes | | ADMA = asymmetric dimethylarginine | | AMI = acute myocardial infarction | | BSL = blood sugar level | | NO = nitric oxide | | PRP = platelet-rich plasma | | SC = subcutaneous |
|
This article has been cited by other articles:

|
 |

|
 |
 
V. Randriamboavonjy and I. Fleming
Insulin, Insulin Resistance, and Platelet Signaling in Diabetes
Diabetes Care,
April 1, 2009;
32(4):
528 - 530.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Dandona, A. Chaudhuri, H. Ghanim, and P. Mohanty
Insulin as an anti-inflammatory and antiatherogenic modulator.
J. Am. Coll. Cardiol.,
February 3, 2009;
53(5 Suppl):
S14 - S20.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Manrique, G. Lastra, J. Palmer, M. Gardner, and J. R. Sowers
Review: Aspirin and Diabetes Mellitus: revisiting an old player
Therapeutic Advances in Cardiovascular Disease,
February 1, 2008;
2(1):
37 - 42.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. P. Giugliano and E. Braunwald
The Year in Non ST-Segment Elevation Acute Coronary Syndrome
J. Am. Coll. Cardiol.,
October 2, 2007;
50(14):
1386 - 1395.
[Full Text]
[PDF]
|
 |
|
|